Walloon medtech company Nomics has successfully raised €3.5 million from private investors and the Walloon Region (SPW), aiming to speed up the adoption of its sleep apnea detection and diagnostic tests. For context, sleep disorders are estimated to affect approximately 20% of the population.
Walloon medtech company Nomics has successfully raised €3.5 million from private investors and the Walloon Region (SPW), aiming to speed up the adoption of its sleep apnea detection and diagnostic tests. For context, sleep disorders are estimated to affect approximately 20% of the population.
Located in the Sart-Tilman Science Park in Liège, Nomics has developed a range of devices for screening, diagnosing, and measuring treatment efficacy for patients suffering from Obstructive Sleep Apnea Syndrome (OSAS). This is the most common sleep-related respiratory disorder. When OSAS is not accurately diagnosed and treated, it can have serious health consequences.
Designed to be performed at home in a non-invasive manner, Nomics' sleep tests offer doctors a simple and reliable solution for their patients. A decision-support platform provided by Nomics aids physicians in all stages of result validity and analysis.
Following an initial funding round of €1 million in February 2022 from its existing shareholders (NOSHAQ, INVEST FOR JOBS (IFJ), and company management), Nomics has successfully completed a second round of funding, raising €3.5 million. This round included contributions of €1.5 million from the management team, Belgian entrepreneur investors, and INVEST FOR JOBS, and €2 million from the Walloon Public Service (SPW).
"The JAWAC technology developed by Nomics makes patient nighttime recording faster, simpler (done at home), and as precise as polysomnography carried out in a hospital setting. We strongly believe in the potential of this Belgian innovation to make patients' lives easier and offer the medical community an effective solution in a field that affects an ever-growing number of patients," says Christophe Picard, CEO of INVEST FOR JOBS. He further adds, "Didier Leclercq, CEO, and his team have done remarkable work in defining and refining the strategic positioning of the JAWAC technology and its numerous possibilities. They have our full confidence to ensure that Nomics takes its final leap forward."
"Our JAWAC sensor allows us to assess jaw movement and measure mouth opening. When a person has sleep respiratory disorders, obstructive events are strongly correlated with mouth opening. But we go further: we interpret the results provided. Currently, we are the only ones able to offer this decision-support to physicians through our platform. We warmly thank the investors who trust us, as well as our loyal shareholders," comments Didier Leclercq, CEO of Nomics.
The funding will enable Nomics to:
Founded in 2002 and based in the Sart-Tilman Science Park in Liège, Nomics aims to make sleep medicine accessible to all patients and healthcare professionals. Using its patented JAWAC technology that measures mandibular activity, Nomics provides quality outpatient solutions for the screening, diagnosis, and measurement of therapeutic efficacy for sleep respiratory disorders. Its technology makes patients' nighttime recording faster, simpler, and most importantly, as precise as polysomnography conducted in a hospital setting.
These articles might interest you
Cardiologists should be aware of the significant prevalence of respiratory sleep disorders and the intricate link between cardiovascular and…
Sleep apnea is often associated with adults, particularly older individuals. However, this disorder can also affect children, with potential…